iNtRON Biotechnology, Inc. (KOSDAQ:048530)
South Korea · Delayed Price · Currency is KRW 2,850.00
+50.00 (1.79%)
Sep 1, 2026, 3:30 PM KST
iNtRON Biotechnology Market Cap
iNtRON Biotechnology has a market cap or net worth of 86.5 billion as of September 1, 2026. Its market cap has decreased by -28.38% in one year.
Market Cap
86.50B
Enterprise Value
48.08B
Revenue
5.74B
Ranking
n/a
PE Ratio
n/a
Stock Price
2,850.00
ChartMarket Cap Chart
Since January 26, 2011, iNtRON Biotechnology's market cap has decreased from 95.30B to 86.50B, a decrease of -9.24%. That is a compound annual growth rate of -0.62%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 1, 2026 | 86.50B | -15.81% |
| Dec 30, 2025 | 102.75B | -44.03% |
| Dec 30, 2024 | 183.56B | -37.01% |
| Dec 28, 2023 | 291.42B | 7.98% |
| Dec 29, 2022 | 269.88B | -61.99% |
| Dec 30, 2021 | 710.00B | -22.41% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Anterogen.Co.,Ltd. | 151.39B |
| Helixmith | 142.75B |
| GC Genome | 140.01B |
| Genexine | 120.29B |
| MedPacto | 95.46B |
| Vaxcell-Bio Therapeutics | 93.15B |
| Prestige BioPharma | 78.13B |
| Amicogen | 67.49B |